Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009015023 | Skin | AK | establishment of protein localization to membrane | 45/1910 | 260/18723 | 2.84e-04 | 2.99e-03 | 45 |
GO:007162114 | Skin | AK | granulocyte chemotaxis | 26/1910 | 125/18723 | 3.17e-04 | 3.24e-03 | 26 |
GO:009752915 | Skin | AK | myeloid leukocyte migration | 39/1910 | 220/18723 | 4.30e-04 | 4.05e-03 | 39 |
GO:007097219 | Skin | AK | protein localization to endoplasmic reticulum | 17/1910 | 74/18723 | 1.04e-03 | 8.19e-03 | 17 |
GO:003059313 | Skin | AK | neutrophil chemotaxis | 21/1910 | 103/18723 | 1.50e-03 | 1.08e-02 | 21 |
GO:009753010 | Skin | AK | granulocyte migration | 27/1910 | 148/18723 | 2.01e-03 | 1.35e-02 | 27 |
GO:007259910 | Skin | AK | establishment of protein localization to endoplasmic reticulum | 11/1910 | 46/18723 | 5.57e-03 | 3.06e-02 | 11 |
GO:19902668 | Skin | AK | neutrophil migration | 22/1910 | 122/18723 | 5.74e-03 | 3.13e-02 | 22 |
GO:007259427 | Skin | cSCC | establishment of protein localization to organelle | 213/4864 | 422/18723 | 1.40e-27 | 5.15e-25 | 213 |
GO:000660527 | Skin | cSCC | protein targeting | 153/4864 | 314/18723 | 2.62e-18 | 3.36e-16 | 153 |
GO:009015024 | Skin | cSCC | establishment of protein localization to membrane | 123/4864 | 260/18723 | 8.34e-14 | 5.18e-12 | 123 |
GO:004873227 | Skin | cSCC | gland development | 167/4864 | 436/18723 | 7.64e-09 | 2.44e-07 | 167 |
GO:003009929 | Skin | cSCC | myeloid cell differentiation | 146/4864 | 381/18723 | 6.38e-08 | 1.61e-06 | 146 |
GO:0070972110 | Skin | cSCC | protein localization to endoplasmic reticulum | 41/4864 | 74/18723 | 7.13e-08 | 1.78e-06 | 41 |
GO:007180610 | Skin | cSCC | protein transmembrane transport | 33/4864 | 59/18723 | 9.93e-07 | 1.78e-05 | 33 |
GO:00650027 | Skin | cSCC | intracellular protein transmembrane transport | 28/4864 | 51/18723 | 1.05e-05 | 1.37e-04 | 28 |
GO:007259916 | Skin | cSCC | establishment of protein localization to endoplasmic reticulum | 26/4864 | 46/18723 | 1.07e-05 | 1.39e-04 | 26 |
GO:00450479 | Skin | cSCC | protein targeting to ER | 24/4864 | 42/18723 | 1.82e-05 | 2.19e-04 | 24 |
GO:00066125 | Skin | cSCC | protein targeting to membrane | 54/4864 | 131/18723 | 9.79e-05 | 9.11e-04 | 54 |
GO:000257324 | Skin | cSCC | myeloid leukocyte differentiation | 76/4864 | 208/18723 | 4.75e-04 | 3.60e-03 | 76 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRP54 | SNV | Missense_Mutation | | c.1139N>C | p.Asp380Ala | p.D380A | P61011 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRP54 | SNV | Missense_Mutation | | c.1340C>T | p.Ser447Phe | p.S447F | P61011 | protein_coding | deleterious(0.02) | possibly_damaging(0.63) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SRP54 | insertion | Frame_Shift_Ins | novel | c.1223_1224insGAAGAAATGCTTCAAGTTGCTAATGCTAT | p.Gly409LysfsTer10 | p.G409Kfs*10 | P61011 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
SRP54 | insertion | Nonsense_Mutation | novel | c.1024_1025insCAAGGCACATAAACTACACCTACTAGGATGAGTAAAAT | p.Met342ThrfsTer9 | p.M342Tfs*9 | P61011 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRP54 | SNV | Missense_Mutation | | c.755G>T | p.Gly252Val | p.G252V | P61011 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SRP54 | SNV | Missense_Mutation | novel | c.1067N>T | p.Gly356Val | p.G356V | P61011 | protein_coding | deleterious(0.05) | possibly_damaging(0.822) | TCGA-VS-A9UM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRP54 | SNV | Missense_Mutation | novel | c.508N>G | p.Ile170Val | p.I170V | P61011 | protein_coding | tolerated(0.4) | benign(0) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SRP54 | SNV | Missense_Mutation | | c.851C>A | p.Pro284His | p.P284H | P61011 | protein_coding | tolerated(0.09) | possibly_damaging(0.663) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRP54 | SNV | Missense_Mutation | novel | c.702N>T | p.Lys234Asn | p.K234N | P61011 | protein_coding | deleterious(0.04) | possibly_damaging(0.511) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SRP54 | SNV | Missense_Mutation | | c.184N>T | p.Leu62Phe | p.L62F | P61011 | protein_coding | tolerated(0.58) | benign(0.003) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |